In this review:
IMpower010: adjuvant atezolizumab extends DFS
EMERGING: no survival benefit to neoadjuvant erlotinib in stage 3A (N2) disease
Neoadjuvant nivolumab does not impact ability to proceed to curative therapy
Front-line nivolumab/ipilimumab elicits durable survival benefits in advanced NSCLC
Combining immunotherapy and chemotherapy improves survival in advanced disease
TACTI-002 demonstrates antitumour activity of front-line eftilagimod alpha/pembrolizumab
HER3-DXd shows promising activity in EGFR inhibitor-resistant EGFR mutated NSCLC
Incidence and heterogeneity of EGFR resistance mutations
Aumolertinib delays disease progression in EGFR mutated disease
Racial disparities in biomarker testing and clinical trial enrolment in the US
Please login below to download this issue (PDF)